ArticleFrontiers in nutrition2025
Sex-specific prognostic utility of the sarcopenia index in all-cause mortality risk for patients with heart failure.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The sarcopenia index (SI), derived from serum creatinine and cystatin C levels, has emerged as a novel and accessible biomarker for predicting clinical outcomes. However, its sex-specific prognostic utility in heart failure (HF) remains poorly understood. This study aimed to investigate the association between SI and all-cause mortality in HF, with a focus on sex-specific differences. Methods: A retrospective cohort of 753 patients (median age: 69 years; 61% male) diagnosed with HF from a tertiary hospital in China was analyzed. Cox regression models and Kaplan-Meier survival analyses were utilized to evaluate the relationship between SI and all-cause mortality. Stratified analyses based on sex were performed, and the incremental predictive value of SI was assessed by integrating it into traditional risk models. Results: Over a median follow-up of 537 days, 143 deaths occurred. In adjusted models, a lower SI was significantly associated with an increased risk of all-cause mortality in male patients (hazard ratio: 0.98 per unit increase, 95% confidence interval: 0.97-0.99, Conclusion: The SI serves as a robust sex-specific predictor of all-cause mortality in HF, demonstrating significant prognostic value in males but limited utility in females. These findings highlight the potential of SI as a cost-effective addition to existing risk stratification models for male patients with HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.